Literature DB >> 16987081

Advances in the treatment of prostate cancer.

Mark Pomerantz1, Philip Kantoff.   

Abstract

Several recent advances have been made in the management of prostate cancer. Active surveillance is an increasingly attractive and reasonable approach for those with low-volume, low-risk disease. For locally advanced or localized high-risk disease, neoadjuvant and adjuvant therapies are emerging as the standard of care. Innovative uses of traditional hormonal treatments can potentially limit common side effects. Recent data also support the utility of second-line hormonal therapy. For the first time, a survival advantage with the use of chemotherapy has been established. Much work is under way to augment its efficacy with novel agents such as targeted therapeutics and tumor vaccines. Recent scientific breakthroughs suggest additional strategies in treating prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16987081     DOI: 10.1146/annurev.med.58.101505.115650

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  15 in total

Review 1.  Integrins in prostate cancer progression.

Authors:  Hira Lal Goel; Jing Li; Sophia Kogan; Lucia R Languino
Journal:  Endocr Relat Cancer       Date:  2008-06-04       Impact factor: 5.678

2.  Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display.

Authors:  Jessica R Newton Northup; Susan L Deutscher
Journal:  Comb Chem High Throughput Screen       Date:  2016       Impact factor: 1.339

3.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

4.  α(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.

Authors:  David S Garlick; Jing Li; Brian Sansoucy; Tao Wang; Leeanne Griffith; Tj Fitzgerald; Julie Butterfield; Bridget Charbonneau; Shelia M Violette; Paul H Weinreb; Timothy L Ratliff; Chun-Peng Liao; Pradip Roy-Burman; Michele Vietri; Jane B Lian; Gary S Stein; Dario C Altieri; Lucia R Languino
Journal:  Am J Transl Res       Date:  2012-04-10       Impact factor: 4.060

5.  Design of curcumin loaded cellulose nanoparticles for prostate cancer.

Authors:  Murali Mohan Yallapu; Mitch Ray Dobberpuhl; Diane Michele Maher; Meena Jaggi; Subhash Chand Chauhan
Journal:  Curr Drug Metab       Date:  2012-01       Impact factor: 3.731

6.  Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.

Authors:  Prashanth K Jayanna; Deepa Bedi; James W Gillespie; Patricia DeInnocentes; Tao Wang; Vladimir P Torchilin; Richard C Bird; Valery A Petrenko
Journal:  Nanomedicine       Date:  2010-02-04       Impact factor: 5.307

7.  Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Authors:  Weisheng Zhang; Brian B Haines; Clay Efferson; Joe Zhu; Chris Ware; Kaiko Kunii; Jennifer Tammam; Minilik Angagaw; Marlene C Hinton; Heike Keilhack; Cloud P Paweletz; Theresa Zhang; Chris Winter; Sriram Sathyanarayanan; Jonathan Cheng; Leigh Zawel; Stephen Fawell; Gary Gilliland; Pradip K Majumder
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 8.  Cognitive effects of hormone therapy in men with prostate cancer: a review.

Authors:  Christian J Nelson; Jennifer S Lee; Maria C Gamboa; Andrew J Roth
Journal:  Cancer       Date:  2008-09-01       Impact factor: 6.860

9.  cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines.

Authors:  G Haramis; Z Zhou; A Pyriochou; M Koutsilieris; C Roussos; A Papapetropoulos
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

10.  Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.

Authors:  Shu-Ben Sun; Ping Liu; Fa-Ming Shao; Qi-Long Miao
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.